Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on...
ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential fo...
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant s...
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigation...
At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinica...
At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinica...
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of...
Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company de...
